Drug
Hrs 4642 AG
Hrs 4642 AG: highest development phase Phase 3, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| HRS-4642 + AG NCT07232875 | Phase 3 | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting |
Latest
No recent events.
Follow Hrs 4642 AG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.